CN102210742B - 薄荷素油在制备治疗胆汁淤积性肝病的药物中的应用 - Google Patents
薄荷素油在制备治疗胆汁淤积性肝病的药物中的应用 Download PDFInfo
- Publication number
- CN102210742B CN102210742B CN 201010142961 CN201010142961A CN102210742B CN 102210742 B CN102210742 B CN 102210742B CN 201010142961 CN201010142961 CN 201010142961 CN 201010142961 A CN201010142961 A CN 201010142961A CN 102210742 B CN102210742 B CN 102210742B
- Authority
- CN
- China
- Prior art keywords
- liver disease
- cholestatic liver
- oleum menthae
- bile
- rat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010008635 Cholestasis Diseases 0.000 title claims abstract description 54
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 239000001525 mentha piperita l. herb oil Substances 0.000 title abstract 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 16
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 15
- 229960002568 ethinylestradiol Drugs 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 10
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 5
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 5
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 5
- 201000002161 intrahepatic cholestasis of pregnancy Diseases 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000000941 bile Anatomy 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 24
- 108010082126 Alanine transaminase Proteins 0.000 description 18
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 17
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 17
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 17
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 12
- 208000019423 liver disease Diseases 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000007870 cholestasis Effects 0.000 description 6
- 231100000359 cholestasis Toxicity 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 5
- 230000007872 intrahepatic cholestasis Effects 0.000 description 5
- 206010025482 malaise Diseases 0.000 description 5
- 229960001661 ursodiol Drugs 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000232 gallbladder Anatomy 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 3
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 201000001883 cholelithiasis Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 229930007503 menthone Natural products 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JBDOSUUXMYMWQH-UHFFFAOYSA-N 1-naphthyl isothiocyanate Chemical compound C1=CC=C2C(N=C=S)=CC=CC2=C1 JBDOSUUXMYMWQH-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010008617 Cholecystitis chronic Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000004212 intestinal function recovery Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010019754 Hepatitis cholestatic Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- -1 TBA Proteins 0.000 description 1
- 206010048211 Xanthelasma Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 231100000838 cholestatic hepatitis Toxicity 0.000 description 1
- 201000002816 chronic venous insufficiency Diseases 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000004664 etidronic acid derivatives Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010142961 CN102210742B (zh) | 2010-04-09 | 2010-04-09 | 薄荷素油在制备治疗胆汁淤积性肝病的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010142961 CN102210742B (zh) | 2010-04-09 | 2010-04-09 | 薄荷素油在制备治疗胆汁淤积性肝病的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102210742A CN102210742A (zh) | 2011-10-12 |
CN102210742B true CN102210742B (zh) | 2013-06-05 |
Family
ID=44742427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010142961 Active CN102210742B (zh) | 2010-04-09 | 2010-04-09 | 薄荷素油在制备治疗胆汁淤积性肝病的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102210742B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105832856A (zh) * | 2016-06-12 | 2016-08-10 | 莫佳 | 治疗肝胆疾病的中药制剂及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1358530A (zh) * | 2001-10-29 | 2002-07-17 | 江苏康缘药业股份有限公司 | 一种治疗肝胆结石的溶石性药物及制备方法 |
-
2010
- 2010-04-09 CN CN 201010142961 patent/CN102210742B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1358530A (zh) * | 2001-10-29 | 2002-07-17 | 江苏康缘药业股份有限公司 | 一种治疗肝胆结石的溶石性药物及制备方法 |
Non-Patent Citations (3)
Title |
---|
中医药治疗妊娠期肝内胆汁淤积症28例;刘惠英;《中国中医急症》;20030630;第12卷(第3期);276页 * |
刘惠英.中医药治疗妊娠期肝内胆汁淤积症28例.《中国中医急症》.2003,第12卷(第3期),276页. |
艾丽萍,徐志斌.中药药浴治疗淤胆型肝炎30例.《中西医结合肝病杂志》.1999,第9卷(第2期),43. * |
Also Published As
Publication number | Publication date |
---|---|
CN102210742A (zh) | 2011-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ni et al. | Combating COVID-19 with integrated traditional Chinese and Western medicine in China | |
Ma et al. | A review of pharmacological and clinical studies on the application of Shenling Baizhu San in treatment of Ulcerative colitis | |
CN103619333A (zh) | 钩吻素子在制备治疗类风湿性关节炎药物中的应用 | |
Wei et al. | Antiviral effects of Ma Huang Tang against H1N1 influenza virus infection in vitro and in an ICR pneumonia mouse model | |
CN103830577A (zh) | 一种治疗肝胆结石和肾结石的药物组合物及其用途 | |
Zheng et al. | Study on the mechanism of Huangqin Decoction on rats with ulcerative colitis of damp-heat type base on mtDNA, TLR4, p-PI3K, p-Akt protein expression and microbiota | |
Zhang et al. | Elevated system exposures of baicalin after combinatory oral administration of rhein and baicalin: Mainly related to breast cancer resistance protein (ABCG2), not UDP-glucuronosyltransferases | |
CN102614230B (zh) | 一种治疗类风湿性关节炎的药物组合物及其制备方法和用途 | |
Ye et al. | Alleviation of non-alcoholic fatty liver disease by Huazhi Fugan Granules is associated with suppression of TLR4/NF-κB signaling pathway | |
CN102210742B (zh) | 薄荷素油在制备治疗胆汁淤积性肝病的药物中的应用 | |
Bai et al. | Potential anti-gout properties of Wuwei Shexiang pills based on network pharmacology and pharmacological verification | |
CN102885928B (zh) | 一种治疗黄疸的中药注射剂及其制备方法 | |
Li et al. | A narrative review of clinical studies of herbal treatment of difficult to manage asthma | |
CN103316166B (zh) | 一种治疗痔疮的藏药及其制备方法 | |
CN105944032B (zh) | 一种治疗肝内胆汁淤积性黄疸疾病的中药组合物及其应用 | |
CN102526256B (zh) | 治疗肝炎的药 | |
CN101371896B (zh) | 一种治疗子宫内膜异位症的药物制剂及其制备方法 | |
CN103845558A (zh) | 一种用于治疗肝炎的中药 | |
CN104435293B (zh) | 异型南五味子总三萜乙醇提取物在制备抗关节炎药物中的应用 | |
CN104382973B (zh) | 细辛总挥发油提取物及提取方法和在制备治疗慢性咳嗽药物中的用途 | |
CN103156961B (zh) | 一种用于感冒风寒,肺胃郁热的药物组合物 | |
CN102671171B (zh) | 一种治疗鼻炎的中药制剂 | |
CN102940621B (zh) | 甲基阿魏酸在制备预防和治疗肝纤维化药物中的应用 | |
Yang et al. | Differential absorption and metabolic characteristics of organic acid components in pudilan xiaoyan oral liquid between young rats and adult rats | |
CN104887775A (zh) | 一种治疗新生儿硬肿症的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application |
Correction item: Applicant Correct: Sichuan Jishengtang Pharmaceutical Co., Ltd. False: Sichuan Jishengtang Pharmaceuticals Co.,Ltd. Number: 41 Volume: 27 |
|
CI02 | Correction of invention patent application |
Correction item: Applicant Correct: Sichuan Jishengtang Pharmaceutical Co., Ltd. False: Sichuan Jishengtang Pharmaceuticals Co.,Ltd. Number: 41 Page: The title page Volume: 27 |
|
ERR | Gazette correction |
Free format text: CORRECT: APPLICANT; FROM: SICHUAN JISHENGTANG PHARMACEUTICALS CO.,LTD. TO: SICHUAN JISHENGTANG PHARMACEUTICALS CO., LTD. |
|
RECT | Rectification | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |